BCLI BrainStorm Cell Therapeutics Inc.: Rasio rega marang prakiraan pendapatan
Brainstorm Cell (BCLI) minimizes infrastructure risks by utilizing external cGMP facilities for the production of cellular products. The forward price-to-sales ratio confirms this strategy, with the metric serving as the target level. Business development depends on clinical success in treating ALS rather than market cycles. Strict sanitary control during the disposal of biomaterials ensures the environmental safety of the research.
Ringkesan rincian data analitis BrainStorm Cell Therapeutics Inc. (BCLI)
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Brainstorm Cell|BCLI - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Brainstorm Cell|BCLI - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku BrainStorm Cell Therapeutics Inc.|BCLI - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BrainStorm Cell Therapeutics|Rasio cepet brainstorm-cell.com
- data bathi bisnis lan rasio investasi:
BCLI - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Brainstorm Cell|BCLI - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep Brainstorm Cell Therapeutics, Inc.|BCLI - Rasio rega marang bathi tumrap wutah|Pangali EV/EBITDA BrainStorm Cell Therapeutics Inc.|BCLI - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan BrainStorm Cell Therapeutics|BCLI - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan brainstorm-cell.com|BCLI - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Brainstorm Cell
- data dodolan lan asil:
Analisis wiwitan perusahaan:BCLI (BrainStorm Cell Therapeutics)
The specifics of Brainstorm Cell (BCLI) and its long-term anticipation of FDA approval make the forward price-to-sales ratio a key tool for assessing the business's resilience to cost inflation. This chart reflects market expectations for future sales, allowing investors to promptly identify capital vulnerabilities and the impact of R&D expenses on asset value without waiting for quarterly reports.
Karo sapa Brainstorm Cell saingan
Rasio rega marang prakiraan pendapatan Biogen BIIB|Neurocrine (NBIX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RGC - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan AXSM (Axsome Corp)|ACADIA Pharmaceuticals (ACAD) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan xenon-pharma.com|Multiplikator forward rega marang pendapatan VKTX|SUPN: Rega forward marang dodolan|Multiplikator Forward P/S CPRX|Multiplikator forward rega marang pendapatan Denali Corp DNLI|Multiplikator Forward P/S HRMY (Harmony Biosciences)|biohavenpharma.com (BHVN) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|AMLX - Rasio rega marang prakiraan pendapatan|TRVI: Rasio rega marang prakiraan pendapatan|Praxis Medicines (PRAX) - Rasio rega marang prakiraan pendapatan|AVXL (Anavex Life Sciences Corp) - Rasio rega marang prakiraan pendapatan|CBLL (CeriBell, Inc.) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan PRTA|Multiplikator Forward P/S ALEC|Multiplikator forward rega marang pendapatan Annexon Biosciences ANNX|Rasio rega marang prakiraan pendapatan Omeros OMER|Neurogene Therapeutics - Rasio rega marang prakiraan pendapatan|AC Immune - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake voyagertherapeutics.com VYGR|Neumora Therapeutics, Inc. (NMRA) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan SCLX|TVGN (Tevogen Bio Holdings, Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alpha Cognition Corp ACOG|Multiplikator forward rega marang pendapatan CGTX (Cognition Therapeutics)|Multiplikator Forward P/S inhibikase.com (IKT)|Rasio rega marang prakiraan pendapatan Cassava Sciences SAVA|Rega forward marang dodolan ASRT|COYA - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vistagen Therapeutics|OVID: Multiplikator Forward P/S|ABOS (acumenpharm.com) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan CervoMed|ATHE: Rega forward marang dodolan|Multiplikator Forward P/S CLNN|Multiplikator Forward P/S pepgen.com (PEPG)|Multiplikator Forward P/S JUNS (Jupiter Neurosciences Inc)|Rasio kapitalisasi marang dodolan sing dikarepake relmada.com (RLMD)|ANVS - Rasio rega marang prakiraan pendapatan|GRCE (Grace Therapeutics, Inc.) - Kapitalisasi marang prakiraan pendapatan|Firefly Neuroscience Inc (AIFF) - Rasio rega marang prakiraan pendapatan|KLTO - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan NRSN|RVPH (revivapharma.com) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan MetaVia Inc (MTVA)|NRXS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Helius Medical Technologies HSDT|Rega forward marang dodolan PASG|NEUP - Rasio rega marang prakiraan pendapatan|minervaneurosciences.com (NERV) - Multiplikator forward rega marang pendapatan|ATHA (Athira Pharma) - Multiplikator forward rega marang pendapatan|Addex Therapeutics Ltd. - Rega forward marang dodolan|ALZN (Alzamend Neuro Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Cyclerion (CYCN)|Multiplikator Forward P/S PTIX|KTTA - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Cortigent CRGT|Avenue Therapeutics Inc. - Rasio rega marang prakiraan pendapatan|CARA - Rasio rega marang prakiraan pendapatan|CHRO: Rasio rega marang prakiraan pendapatan|ELYM: Multiplikator Forward P/S|ITCI (Intra-Cellular Therapies, Inc.) - Rasio rega marang prakiraan pendapatan|LBPH (Longboard Pharmaceuticals, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Marinus Pharmaceuticals Inc (MRNS)|Rasio rega marang prakiraan pendapatan NKGen (NKGN)|Rasio rega marang prakiraan pendapatan NRBO (NeuroBo Pharma)|Multiplikator Forward P/S SAGE (Sage Therapeutics, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake synaptogen.com (SNPX)|TRVN - Rasio rega marang prakiraan pendapatan|VIGL (Vigil Neuroscience) - Kapitalisasi marang prakiraan pendapatan|WENA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Cerevel Corp (CERE)
